ClinicalTrials.gg
CompletedNCT00081796Updated Aug 21, 2008

Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer

A Phase 3 interventional study of larotaxel (RPR109881, XRP9881) and capecitabine in Breast Cancer and Metastases, sponsored by Sanofi. Completed at 187 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-08-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
27th of 227
438 · median 54
Started
2004
with 18 others
Phase 3
45 of 233
5 open now
Registered
18th of 233
by date

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 27th largest by enrollment of the 227 interventional ones that give a count, is one of 19 that started in 2004, is one of 45 in phase 3, and was the 18th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to determine if RPR109881 is a better treatment than capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from docetaxel and/or paclitaxel.

Read the detailed description

All patients in this trial will receive either the investigational drug or capecitabine, a chemotherapy drug that is already approved to treat your disease. These drugs prevent tumor cells from dividing, so they may stop growing or die. The investigational drug in this clinical trial is a chemotherapy drug given through the vein once every three weeks. Patients who receive capecitabine will receive this drug by mouth for 14 days, every 21 days.

03

Conditions studied

  • Breast Cancer
  • Metastases

Keywords

  • Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria

In order to be eligible for this trial you must:

  • Have a diagnosis of breast cancer that is now (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that cannot be removed by surgery.
  • Have received previous treatment with anthracyclines (e.g., adriamycin, Doxorubicin) and taxanes (e.g., paclitaxel, docetaxel, Taxol®, Taxotere®) for your breast cancer and your doctor has determined that these treatment are no longer of benefit to you.
  • Be at least 18 years of age.
  • Not be taking other treatments for your cancer at the time you enter this trial.
  • Not be pregnant.

Additionally, there are other criteria for study entry that a doctor participating in this study will need to review in detail with you and clinical assessments may need to be performed (e.g., lab tests, CT scans).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
438 participants (actual)
06

What researchers measure

Primary outcomes

  1. Time to tumor progression.

Secondary outcomes

  1. Overall survival.

07

Study locations

187 sites
  • Birmingham, Alabama 35216, United States
  • Tucson, Arizona 85704, United States
  • Little Rock, Arkansas 72205, United States
  • Bakersfield, California 93309, United States
  • Burbank, California 91505, United States
  • Concord, California 94520, United States
  • Fountain Valley, California 92708, United States
  • Fresno, California 93720, United States
  • Fullerton, California 92835, United States
  • Gilroy, California 95020, United States
  • Long Beach, California 90806, United States
  • Los Angeles, California 90095, United States
  • Monterey Park, California 91754, United States
  • Northridge, California 91328, United States
  • Oxnard, California 93030, United States
  • Pamona, California 91767, United States
  • Pomona, California 91767, United States
  • Porterville, California 93257, United States
  • Redondo Beach, California 90272, United States
  • San Diego, California 92123, United States
  • San Francisco, California 94115, United States
  • Santa Barbara, California 93105, United States
  • Soquel, California 95073, United States
  • Vista, California 92081, United States
  • New London, Connecticut 06320, United States
  • Newark, Delaware 19718, United States
  • Fort Lauderdale, Florida 33308, United States
  • Ft Lauderdale, Florida 33316, United States
  • Gainsville, Florida 32605, United States
  • Jacksonville, Florida 32209, United States
  • Lake Worth, Florida 33461, United States
  • Orlando, Florida 32804, United States
  • West Palm Beach, Florida 33401, United States
  • Lawrenceville, Georgia 30045, United States
  • Macon, Georgia 31201, United States
  • Marietta, Georgia 30060, United States
  • Roswell, Georgia 30076, United States
  • Centralia, Illinois 62801, United States
  • Chicago, Illinois 60640, United States
  • Peoria, Illinois 61615, United States
  • Skokie, Illinois 66077, United States
  • Fort Wayne, Indiana 46815, United States
  • New Albany, Indiana 47150, United States
  • Danville, Kentucky 40422, United States
  • Hazard, Kentucky 41701, United States
  • Lexington, Kentucky 40503, United States
  • Lafayette, Louisiana 70503, United States
  • Shreveport, Louisiana 71101, United States
  • Annapolis, Maryland 21401, United States
  • Baltimore, Maryland 21201, United States
  • Southfield, Michigan 48076, United States
  • St. Joseph, Michigan 49085, United States
  • St. Louis, Missouri 63110, United States
  • St. Louis, Missouri 63141, United States
  • Billings, Montana 59101, United States
  • Hackensack, New Jersey 07601, United States
  • Nyack, New York 10960, United States
  • Utica, New York 13502, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28203, United States
  • Charlotte, North Carolina 28204, United States
  • Greenville, North Carolina 27834, United States
  • Raleigh, North Carolina 27609, United States
  • Wilmington, North Carolina 28401, United States
  • Winston-Salem, North Carolina 27103, United States
  • Bismarck, North Dakota 58501, United States
  • Cincinatti, Ohio 45267, United States
  • Cleveland, Ohio 44109, United States
  • Cleveland, Ohio 44195, United States
  • Worthington, Ohio 43085, United States
  • Dunmore, Pennsylvania 18512, United States
  • Hershey, Pennsylvania 17033, United States
  • Kingston, Pennsylvania 18704, United States
  • Kttaning, Pennsylvania 16201, United States
  • Philadelphia, Pennsylvania 19106, United States
  • Philadelphia, Pennsylvania 19115, United States
  • Philadelphia, Pennsylvania 19146, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Charleston, South Carolina 29403, United States
  • Charleston, South Carolina 29425, United States
  • Greenville, South Carolina 29615, United States
  • Nashville, Tennessee 37205, United States
  • Dallas, Texas 75390, United States
  • Fort Worth, Texas 76104, United States
  • Richardson, Texas 75082, United States
  • Abingdon, Virginia 24211, United States
  • Arlington, Virginia 22205, United States
  • Kirkland, Washington 98034, United States
  • Spokane, Washington 99202, United States
  • Huntington, West Virginia 25701, United States
  • Buenos Aires, Argentina
  • Capital Federal, Argentina
  • Santa Fe, Argentina
  • Melbourne, Australia
  • Perth, Australia
  • St. Leonards, Australia
  • Sydney, Australia
  • Bludesch, Austria
  • Vienna, Austria
  • Sorocaba, San Paulo, Brazil

Showing the first 100 of 187 sites across 26 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2004
First posted
Apr 22, 2004
Start
Apr 2004
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
Aug 21, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00081796
Lead sponsor
Sanofi
First posted
Apr 22, 2004
Start date
Apr 2004
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Aug 21, 2008

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Larotaxel · Capecitabine

Start the discussion